Efficacy of a new once-daily long-acting inhaled  2-agonist indacaterol versus twice-daily formoterol in COPD

Dahl, Ronald; Chung, Kian Fan; Buhl, Roland; Magnussen, H; Nonikov, V E; Jack, Damon; Bleasdale, Patricia; Owen, Roger; Higgins, Mark; Krämer, Benjamin; Investigators, Safety Study

doi:10.1136/thx.2009.125435

Cited by 260 publications

(277 citation statements)

References 23 publications

Supporting

Mentioning

247

Contrasting

Unclassified

Order By: Relevance

“…Comparable safety of these two treatments was also observed in the previous 6-month open-label comparison [2], and indacaterol has previously demonstrated an acceptable tolerability and safety profile with the 300 mg and the abovetherapeutic 600 mg doses given for up to 1 yr compared with placebo [12]. Overall, these results present a reassuring safety profile for this new bronchodilator.…”

Section: Discussionsupporting

confidence: 64%

“…While potentially interesting, the actual differences of 30-40 mL are very small and well below the 100-140 mL level of clinical relevance [14]. Previously, indacaterol has been reported to have a similar effect in patients with differing COPD severities [12].…”

Section: Discussionmentioning

confidence: 99%

“…Previous study results provided an assumed treatment difference (indacaterol-tiotropium) of 40 mL for trough FEV1 at week 12 [2], with a standard deviation of 225 mL [2,11,12]. A sample size of 666 evaluable patients per treatment group was needed to detect this difference as statistically significant at the 5% level (two-sided) with 90% power.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

Buhl¹,

Dunn²,

Disdier³

et al. 2011

Eur Respir J

Self Cite

130

View full text Add to dashboard Cite

on behalf of the INTENSITY study investigators ABSTRACT: Two, once daily (q.d.) inhaled bronchodilators are available for the treatment of chronic obstructive pulmonary disease (COPD): the b 2 -agonist indacaterol and the anticholinergic tiotropium. This blinded study compared the efficacy of these two agents and assessed their safety and tolerability.Patients with moderate-to-severe COPD were randomised to treatment with indacaterol 150 mg q.d. (n5797) or tiotropium 18 mg q.d. (n5801) for 12 weeks.After 12 weeks, the two treatments had similar overall effects on ''trough'' (24 h post-dose) forced expiratory volume in 1 s. Indacaterol-treated patients had greater improvements in transition dyspnoea index (TDI) total score (least squares means 2.01 versus 1.43; p,0.001) and St George's Respiratory Questionnaire (SGRQ) total score (least squares means 37.1 versus 39.2; p,0.001; raw mean change from baseline -5.1 versus -3.0), and were significantly more likely to achieve clinically relevant improvements in these end-points (indacaterol versus tiotropium odds ratios of 1.49 for TDI and 1.43 for SGRQ, both p,0.001). Adverse events were recorded for 39.7% and 37.2% of patients in the indacaterol and tiotropium treatment groups, respectively. The most frequent adverse events were COPD worsening, cough and nasopharyngitis.Both bronchodilators demonstrated spirometric efficacy. The two treatments were well tolerated with similar adverse event profiles. Compared with tiotropium, indacaterol provided significantly greater improvements in clinical outcomes.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

Buhl¹,

Dunn²,

Disdier³

et al. 2011

Eur Respir J

Self Cite

130

View full text Add to dashboard Cite

show abstract

“…10 Dahl et al used indacaterol 150 mcg and formoterol 12 mcg for 1 year in COPD patient found indacaterol more efficacious. 6 Also MEHLER et al 7,8 showed that Overall ADR noticed over a period of 24 weeks were less and comparable in both groups. No SAE were reported.…”

Section: Discussionmentioning

confidence: 99%

A comparative study of efficacy and safety of combination of indacaterol and tiotropium versus formoterol and budesonide in moderate to severe chronic obstructive pulmonary disease

Bende

Dudhgaonkar²,

Jagdhani³

2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

“…Indacaterol has also demonstrated superior bronchodilation and clinical efficacy compared with the twice-daily LABAs salmeterol [66] and formoterol [67], and is at least as effective in improving lung function and symptoms as tiotropium [68,69].…”

Section: Indacaterolmentioning

confidence: 99%

Addressing unmet needs in the treatment of COPD

Patalano¹,

Banerji²,

D’Andrea³

et al. 2014

Eur Respir Rev

View full text Add to dashboard Cite

The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting b 2 -agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patientreported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised. @ERSpublications There is a need to optimise COPD treatment, with the aim of improving patients' lives

show abstract

Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily formoterol in COPD

Abstract: Background Indacaterol is a long-acting inhaled b 2 -

Cited by 260 publications

References 23 publications

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

A comparative study of efficacy and safety of combination of indacaterol and tiotropium versus formoterol and budesonide in moderate to severe chronic obstructive pulmonary disease

Addressing unmet needs in the treatment of COPD

Contact Info

Product

Resources

About